<< Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer | Party drinking or drinking problem? >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Filipino | Русский

Scientists report basic findings on critical enzyme's regulation may hold key to understanding how to better treat an array of disorders

Published on November 19, 2008 at 7:29 PM · No Comments

Scientists at St. Jude Children's Research Hospital have gained new insights into regulation of one of the body's enzyme workhorses called calpains.

As the cell's molecular overachievers, calpains function in many cellular processes, including the movement of cells in tissues, the death of damaged cells, insulin secretion, and brain cell and muscle function. The downside of this broad set of responsibilities is that defective or overactive calpains have been linked to an array of disorders, including a form of muscular dystrophy, Type 2 diabetes, gastric cancers, Alzheimer's and Parkinson's diseases, cataracts, and the death of both heart muscle in heart attacks and of brain tissue in stroke and traumatic brain injury.

"Our basic findings on calpain regulation could add useful pieces to the puzzles of these disorders and perhaps reveal targets for drugs to treat them," said Douglas Green, Ph.D., chair of the St. Jude Department of Immunology.

Calpains are triggered by calcium flowing into the cell. This process induces the enzyme to snip apart many target proteins, as part of the cell's regulatory machinery. However, such a critical enzyme needs ultra-precise control, which is the job of another protein called calpastatin. A central question has been how calpastatin is so exquisitely specific in attaching to calpain and inhibiting it --- essentially ignoring other highly similar enzymes in the cell.

In an article published in the November 20, 2008, issue of the journal Nature, Green and his colleagues report new information on the specificity of calpastatin.

"Previous studies on calpastatin had revealed how a few of the parts of the calpastatin molecule attach to calpain in the inhibition process," said Green, the report's senior author. "However, there was no overall picture of calpastatin that revealed how it was so precise in its attachment and potent in its function."

To obtain that overall picture, St. Jude researchers used the analytical technique of X-ray crystallography, with help from nuclear magnetic resonance (NMR) spectroscopy. In this widely used method of determining protein structure, researchers first crystallize a protein to be studied. Then, they direct X-rays through the crystal and deduce the protein structure from the diffraction pattern of those X-rays. To overcome the crystallization bottleneck, a lengthy and unpredictable variable in X-ray crystallography, the investigators used NMR spectroscopy to tailor the perfect enzyme-inhibitor complex.

Tudor Moldoveanu, Ph.D., a postdoctoral fellow in Green's laboratory, performed X-ray structural analysis on such a protein crystal that consisted of a critical part of the calpastatin molecule attached to calpain. The structural picture obtained of the two proteins clutched together clearly revealed why calpastatin so specifically attaches to calpain.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading